GHDX Share Price

Open 29.87 Change Price %
High 30.05 1 Day -0.43 -1.43
Low 29.54 1 Week -1.20 -3.90
Close 29.59 1 Month -3.35 -10.17
Volume 91229 1 Year 3.11 11.74
52 Week High 33.97
52 Week Low 25.66
GHDX Important Levels
Resistance 2 30.06
Resistance 1 29.87
Pivot 29.73
Support 1 29.31
Support 2 29.12
NASDAQ USA Most Active Stocks
DCTH 0.15 -11.76%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
YHOO 52.58 0.00%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
QQQ 141.23 -0.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
More..
NASDAQ USA Top Gainers Stocks
AMCF 0.03 50.00%
LOCM 0.09 50.00%
FALC 0.25 38.89%
VRTA 4.50 38.46%
ESMC 0.13 30.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
STXS 0.68 25.93%
OTT 2.39 25.13%
ATRM 1.70 21.43%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PTSX 0.05 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Genomic Health, Inc. (NASDAQ: GHDX)

GHDX Technical Analysis 4
As on 18th Aug 2017 GHDX Share Price closed @ 29.59 and we RECOMMEND Sell for LONG-TERM with Stoploss of 30.68 & Strong Sell for SHORT-TERM with Stoploss of 32.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
GHDX Target for August
1st Target up-side 33.21
2nd Target up-side 34.13
3rd Target up-side 35.05
1st Target down-side 30.59
2nd Target down-side 29.67
3rd Target down-side 28.75
GHDX Other Details
Segment EQ
Market Capital 993752640.00
Sector Healthcare
Industry Medical Laboratories & Research
Offical website http://www.genomichealth.com
GHDX Address
GHDX
301 Penobscot Drive
Redwood City, CA 94063
United States
Phone: 650-556-9300
GHDX Latest News
Interactive Technical Analysis Chart Genomic Health, Inc. ( GHDX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Genomic Health, Inc.
GHDX Business Profile
Genomic Health, Inc. (Genomic Health) is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.